مجله دانشکده پزشکی اصفهان
پیاپی 664 (هفته چهارم اردیبهشت 1401)

The goal of this study was to make a dosimetric comparison between the absorbed dose distribution of the prostate and the organ at risk (OAR) using two different approaches: three-dimensional conformal radiotherapy (3D-CRT) and Intensity-modulated radiotherapy (IMRT), assesed via treatment planning system (TPS) and thermoluminescence dosimetry (TLD).

In this study, 35 patients with prostate cancer undergoing radiation therapy at Milad Hospital in Isfahan were included. Prostate as target and rectum, bladder and femoral head as healthy organ at risk (OAR) were contoured according to Radiation Therapy Oncology Group (RTOG) criteria. Two separate dosimetry programs IMRT and 3D-CRT have been developed for each patient in order to evaluate the dosimetric status of both methods comparatively. These results were then compared with those of the phantom.

The doses to the bladder, rectum, and femoral head were 50.3, 58.6, and 16.4 in IMRT and 59.6, 68.8, and 34.8 in 3D-CRT, respectively. The dose measured by TLD in all organs in the phantom was higher than the dose calculated by TPS software in the phantom.

The IMRT method is a better method than 3D-CRT due to better coverage of the target volume and reduction of the cumulative dose of organs at risk (OAR). The dose measured by TLDs was higher than the dose calculated by the treatment planning system, which may be due to the fact that the treatment planning system does not calculate the share of scattered radiation in the absorbed dose of organs.

Recently, researchers have become more interested in the role of thyroid hormones in acute coronary syndromes. In the present study, the serum levels of thyroid hormones in STEMI patients at the time of hospital admission and the it's correlation in the success rate in primary percutaneous intervention which is depicted in the form of ST-resolution was evaluated.

In this study, 500 patients who underwent primary angioplasty in Shahid Madani Tabriz hospital within early 2016 and late 2017 were included. The participants were divided in two groups: group 1 (decrease in ST-resolution less than 50%) and group 2 (decrease in ST-RESOLUTION more than 50%). Correlations between thyroid hormones, ST resolution, mortality and Major Adverse Cardiovascular Events (MACE) were assessed.

The mean age of the patients was 57.22 ± 11.32 years old while 401 patients (80.2%) were male and 99 patients (19.8%) were female. In 152 patients (30.4%) ST resolution was 50% and less (group 1) and in 348 patients (69.6%) ST-RESOLUTION was more than 50%. No significant correlation was found between TSH and FT3 levels and ST resolution. Also, MACE and thyroid hormones didn’t have any correlation.

The finding of the present study showed there was no significant relationship between ST resolution and MACE and FT4, TSH and FT3 levels.

Liver fibrosis is a chronic disease caused by viral infections (such as hepatitis B and C viruses), alcohol abuse, and metabolic and genetic disorders that leads to excessive accumulation of extracellular matrix proteins, including collagen. The progression of liver fibrosis can leads to cirrhosis and liver cancer. In this study, the role of silibinin in the prevention of liver fibrosis progression was investigated.

LX2 cells were cultured in DMEM medium with 10% Fetal Bovine Serum (FBS). In the first stage, cells were treated with TGF-β at a concentration of 2 ng / ml (fibrotic group) for cell damage and fibrotic conditions for 24 hours, then at concentrations of 10, 20, 40, 60 and 80 μM of silibinin (The treatment groups) were treated for 24 hours and the mRNA expression of αSMA, collagen1α, NOX1 and NOX2 genes and the rate of intracellular reactive oxygen species (ROS) production were measured.

The results showed that the mRNA expression of αSMA, collagen1α, NOX1 and NOX2 genes at concentrations of 60 and 80 μM silibinin was significantly reduced compared to the TGF-β group. Also, the rate of intracellular ROS production at 60 and 80 μM concentrations of silibinin was significantly reduced compared to the TGF-β group (P < 0.05).

According to our study, silibinin inhibits the activation of Hepatic stellate cells (HSCs) by reducing the expression of genes involved in the progression of hepatic fibrosis and reduces liver damage caused by excessive production of collagen and reactive oxygen species in vitro. The findings from this study indicate that silybinin may be a potential therapeutic agent in the treatment of liver fibrosis.